Disappointing Results in Blood Disorder Study Prompts Changes
- Shattuck Labs ends SL-172154 lead program
- 40% workforce reduction planned
- Phase 1B study results disappointing
- Focus on early pipeline candidate SL-325 for inflammatory bowel disease
- Restructuring to align with goals and strategy
- Expected restructuring charges $1.5M-$1.75M in Q4
- Cash runway extended to 2027
- Terminates license agreement with Ono Pharmaceutical
Shattuck Labs has decided to discontinue its lead program SL-172154 and reduce its workforce by approximately 40% due to unsatisfactory results from a Phase 1B study on blood disorders. The company, which currently employs 75 people, will now focus on early pipeline candidate SL-325 for inflammatory bowel disease development. Shattuck aims to restructure its workforce and strategy, expecting charges of $1.5M-$1.75M in Q4 and extending its cash runway to 2027. Additionally, it terminates a license agreement with Ono Pharmaceutical.
Factuality Level: 8
Factuality Justification: The article provides accurate information about Shattuck Labs’ decision to discontinue its lead program SL-172154 due to the failure of an early study, their focus shift to SL-325 for inflammatory bowel disease, workforce reduction, and financial implications. It also mentions a terminated license agreement with Ono Pharmaceutical. The information is relevant, objective, and based on company statements.
Noise Level: 3
Noise Justification: The article provides relevant information about a company’s decision to discontinue its lead program due to the failure of an early study and restructure its workforce, as well as details on its future focus and financial implications. However, it lacks in-depth analysis or exploration of broader trends or consequences.
Private Companies: Shattuck Labs,Ono Pharmaceutical
Key People: Colin Kellaher (Author)
Financial Relevance: Yes
Financial Markets Impacted: Shattuck Labs’ stock price and investors may be impacted due to the abandonment of its lead program, layoffs, and termination of a license agreement with Ono Pharmaceutical.
Financial Rating Justification: The article discusses the financial implications for Shattuck Labs, including the abandonment of its lead program, significant workforce reduction, and termination of a potentially valuable license agreement. These factors can impact the company’s stock price and investor sentiment.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.
Deal Size: 200000000
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Down
Magnitude: Large
Affected Instruments: Stocks
www.marketwatch.com 
